Effect of Holy Basil on Subjects With Sensitive Skin
OBSERVATIONAL STUDY OF THE EFFICACY ON SENSITIVE SKIN OF AN ORAL FORMULATION BASED ON PURPLE BASIL, FOR 8 WEEKS IN 2 GROUPS OF 100 VOLUNTEERS
1 other identifier
interventional
200
1 country
1
Brief Summary
Stress can have multiple and varied psychological and clinical impacts on skin diseases (Colavincenzo and Granstein, 2006; Graubard et al., 2021). In particular, psychological stress has been shown to reduce the rebuilding kinetics of the skin barrier when altered and it is suggested that psychological stress may trigger or exacerbate immune-mediated dermatological disorders (Hall et al., 2012). Certain symptoms related to sensitive skin problems (itching, burning, pain, etc.) can lead to sleep disorders associated with stress and anxiety. Conversely, these sleep disorders and anxiety or stress due to external sources are known to promote the appearance of symptoms related to skin sensitivity in patients who are at risk of developing sensitive skin syndrome (Farage, 2022). Expanscience Laboratories, manufacturer of cosmetics and dietary supplements, has identified a HOLY BASIL plant extract as a solution to address the negative impacts of stress on sensitive skin symptoms. The main goal of this double blinded randomized controlled clinical study is to evaluate in vivo the effect of an active ingredient HOLY BASIL incorporated into a food supplement on sensitive skin symptoms related to psychological stress after 28 and 56 consecutive days of a twice-daily intake, in comparison with the baseline and a placebo. Evaluation of the effectiveness of HOLY BASIL will be evaluated using psychometric questionnaires related to stress, sensitive skin and overall perception.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 31, 2026
CompletedFirst Submitted
Initial submission to the registry
September 4, 2026
CompletedFirst Posted
Study publicly available on registry
September 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 18, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 18, 2026
September 10, 2026
September 1, 2026
3 months
September 4, 2026
September 4, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Sensitive skin symptoms
Evaluation using Sensitive Scale-10 (SS-10) questionnaire
At baseline and after 28 days and 56 days
Secondary Outcomes (2)
Perceived stress
At baseline and after 28 days and 56 days
Self perception
After 28 days and 56 days
Study Arms (2)
Active product
ACTIVE COMPARATORAdministration of HOLY BASIL
Placebo product
PLACEBO COMPARATORAdministration of Placebo
Interventions
Eligibility Criteria
You may qualify if:
- Gender: Women
- People aged between 45 and 65 years.
- Presenting sensitive skin (Sensitive Scale 10 ≥ 20) with Tightness ≥ 4 and general malaise ≥ 4.
- People who report being stressed (PSS10 questionnaire ≥ 14) and who report a relationship between skin sensitivity and psychological stress (according to the volunteer's opinion).
- Last participation in a clinical study on the face, which ended at least 8 weeks before the start of this study.
- Washing phase of 15 days without application of products on the face, or oral intake.
You may not qualify if:
- People with gastrointestinal diseases (diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).
- People with allergies to 'purple basil' or its excipients (maltodextrin, magnesium stearate).
- Have other physiological disorders (diabetes, hypertension, dyslipidemia) and/or gallstones.
- Individuals under medical treatment in the weeks prior to the study, which may interfere with the evaluations of the present study.
- People who are pregnant or intend to be pregnant within the study period, as well as people who are breastfeeding.
- People who are within a dietary period outside of their usual habit, or intend to change their eating routine during the study period.
- People participating in another clinical study with similar characteristics (according to the investigator's criteria), during the study period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Laboratoires Expanscience S.A.lead
- Dermaclaim Lab S.L.collaborator
Study Sites (1)
Dermaclaim Lab S.L.
Valencia, Valencia, 46019, Spain
Related Publications (4)
Farage, M. A. (2022). Psychological Aspects of Sensitive Skin: A Vicious Cycle. Cosmetics 2022, Vol. 9, Page 78, 9(4), 78. https://doi.org/10.3390/COSMETICS9040078
BACKGROUNDHall JM, Cruser D, Podawiltz A, Mummert DI, Jones H, Mummert ME. Psychological Stress and the Cutaneous Immune Response: Roles of the HPA Axis and the Sympathetic Nervous System in Atopic Dermatitis and Psoriasis. Dermatol Res Pract. 2012;2012:403908. doi: 10.1155/2012/403908. Epub 2012 Aug 30.
PMID: 22969795BACKGROUNDGraubard R, Perez-Sanchez A, Katta R. Stress and Skin: An Overview of Mind Body Therapies as a Treatment Strategy in Dermatology. Dermatol Pract Concept. 2021 Sep 1;11(4):e2021091. doi: 10.5826/dpc.1104a91. eCollection 2021 Sep.
PMID: 34631261BACKGROUNDColavincenzo ML, Granstein RD. Stress and the skin: a meeting report of the Weill Cornell Symposium on the Science of Dermatology. J Invest Dermatol. 2006 Dec;126(12):2560-1. doi: 10.1038/sj.jid.5700565. No abstract available.
PMID: 17108900BACKGROUND
MeSH Terms
Interventions
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 4, 2026
First Posted
September 10, 2026
Study Start
August 31, 2026
Primary Completion (Estimated)
November 18, 2026
Study Completion (Estimated)
November 18, 2026
Last Updated
September 10, 2026
Record last verified: 2026-09